An interventional study of minimally invasive suprachoroidal drainage in Neovascular Glaucoma, sponsored by Zhongnan Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-01.
Sponsored by Zhongnan Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To explore the efficacy and safety of minimally invasive suprachoroidal drainage for the treatment of advanced neovascular glaucoma
To explore the efficacy and safety of minimally invasive supraporcular drainage in the treatment of advanced neovascular glaucoma, and to record the various basic diseases, ocular conditions, lifestyle, inflammatory markers and other parameters of NVG patients. To compare the safety and efficacy of new surgical methods and traditional surgical methods in order to find an effective treatment for neovascular glaucoma
39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.
This study's planned enrollment of 30 is below the median of 40 across 32 interventional studies indexed under Glaucoma, Neovascular.
Browse Glaucoma, Neovascular studies →Zhongnan Hospital is the lead sponsor of 106 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient will undergo a minimally invasive suprachoroidal drainage procedure
Procedure: minimally invasive suprachoroidal drainage
minimally invasive suprachoroidal drainage
Ocular biological parameters
intraocular pressure
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Ocular biological parameters
visual acuity
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Surgical outcome measures
use of intraocular pressure lowering drugs
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
The success rate of surgery was evaluated according to the specific value of intraocular pressure after surgery
Complete success was defined as IOP within the normal range with no drug dependence, conditional success was defined as IOP within the normal range with drug dependence, and failure was defined as the rest
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
The effective rate of surgery was evaluated according to the amplitude of IOP reduction after surgery and the change in the number of IOP-lowering drugs
Amplitude of IOP reduction: IOP change/initial IOP.The total number of IOP lowering drugs was recorded based on the number of active ingredients
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Surgical outcome measures
complications
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.